title: Mucinous borderline and malignant tumors of the ovary. A clinicopathologic and DNA ploidy study of 92 cases.
abstract: BACKGROUND
  The morphologic spectrum of ovarian mucinous tumors is well known, but the features that predict aggressive behavior are still controversial.
  
  
  METHODS
  Ninety-two cases of primary ovarian mucinous tumors with atypical epithelial proliferation and/or stromal invasion were analyzed histologically and by DNA flow cytometry, and the results were correlated with clinical findings.
  
  
  RESULTS
  The authors reviewed 57 intestinal mucinous borderline tumors (IMBT), 3 endocervical-like mucinous borderline tumors (EMBT), 21 noninvasive mucinous carcinomas (NIMC), and 11 invasive mucinous carcinomas (IMC). The 5-year survival rate for Stage I tumors was: IMBT 100%, EMBT 100%, NIMC 94% and IMC 60%. The 5-year survival of Stage II-IV tumors was: IMBT 50%, NIMC 33% and IMC 0%. Forty-four IMBTs were diploid, and 4 were aneuploid. All six high stage IMBTs were diploid. Two EMBTs were diploid, and one was aneuploid. There were seven diploid, four polyploid, and six aneuploid NIMCs. Two of the three lethal NIMCs were aneuploid. Four IMCs were diploid, and four were aneuploid. Of these, only the diploid Stage I IMCs were nonlethal. All NIMCs that recurred or presented with metastases had been sampled inadequately. High stage tumors with pseudomyxoma peritonei (PP)-type lesions often were associated with pseudomyxoma ovarii of the cellular type.
  
  
  CONCLUSIONS
  Mucinous tumors with stromal invasion or presenting with PP had a definite malignant behavior. All other atypical mucinous tumors, when confined to the ovary and optimally sampled, had an excellent prognosis. DNA ploidy analysis may prove useful in determining the risk of progression, especially in Stage I IMCs.
authors.affiliation: Department of Pathology, University Hospital of Linköping, Sweden.
authors.forename: C
authors.initials: C
authors.lastname: Guerrieri
authors.forename: T
authors.initials: T
authors.lastname: Högberg
authors.forename: S
authors.initials: S
authors.lastname: Wingren
authors.forename: S
authors.initials: S
authors.lastname: Fristedt
authors.forename: E
authors.initials: E
authors.lastname: Simonsen
authors.forename: B
authors.initials: B
authors.lastname: Boeryd
mesh_terms: D002288:Adenocarcinoma, Mucinous / Q000401:mortality / Q000473:pathology* / Q000648:ultrastructure; D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002455:Cell Division; D018291:Cystadenoma, Mucinous / Q000401:mortality / Q000473:pathology* / Q000648:ultrastructure; D004273:DNA, Neoplasm / Q000032:analysis*; D005260:Female; D005434:Flow Cytometry; D006801:Humans; D008875:Middle Aged; D009361:Neoplasm Invasiveness; D009367:Neoplasm Staging; D010051:Ovarian Neoplasms / Q000401:mortality / Q000473:pathology* / Q000648:ultrastructure; D010534:Peritoneal Neoplasms / Q000473:pathology / Q000648:ultrastructure; D011003:Ploidies; D011379:Prognosis; D011553:Pseudomyxoma Peritonei / Q000473:pathology; D015996:Survival Rate
chemical_list: D004273:DNA, Neoplasm